Outset Medical (OM) GC sells shares in tax sell-to-cover trades

Rhea-AI Filing Summary

Outset Medical, Inc.'s General Counsel, John L. Brottem, reported automatic sales of company common stock to cover tax withholding on recently vested equity awards. On January 20, 2026, he sold 9,314 shares of common stock at $5.12 per share, leaving him with 36,957 shares beneficially owned. On January 21, 2026, he sold an additional 1,180 shares at $5.01 per share, resulting in 35,777 shares beneficially owned afterward.

The filing explains that these 10,494 shares were the required number sold to partially cover tax withholding tied to the vesting of 17,997 shares of common stock underlying RSUs granted to him on June 10, 2025. The sales were executed as a “sell to cover” transaction for tax purposes and are described as not discretionary trades by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brottem John L.

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		9,314(1)	D	$5.12	36,957	D
Common Stock	01/21/2026		S		1,180(1)	D	$5.01	35,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover partial tax withholding obligations in connection with the vesting of an aggregate of 17,997 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

	John L Brottem	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Outset Medical (OM) report in this Form 4?

The Form 4 reports that John L. Brottem, General Counsel of Outset Medical, Inc., sold shares of the company’s common stock on January 20 and 21, 2026 in connection with tax withholding on vested RSUs.

How many Outset Medical (OM) shares did John L. Brottem sell and at what prices?

He sold 9,314 shares of common stock on January 20, 2026 at $5.12 per share and 1,180 shares on January 21, 2026 at $5.01 per share.

Why did the Outset Medical (OM) General Counsel sell these shares?

The filing states the 10,494 shares sold were the required number to cover partial tax withholding obligations related to the vesting of 17,997 RSU-based shares. It describes the transactions as a “sell to cover” for taxes rather than discretionary trades.

How many Outset Medical (OM) shares does John L. Brottem own after these transactions?

Following the reported transactions, John L. Brottem beneficially owns 35,777 shares of Outset Medical, Inc. common stock in direct form.

What equity award vesting was tied to these Outset Medical (OM) share sales?

The tax-related sales were connected to the vesting of an aggregate of 17,997 shares of common stock underlying RSUs granted on June 10, 2025 to the reporting person.

Is this Outset Medical (OM) insider sale described as discretionary trading?

No. The explanation specifies that the sale was made to satisfy tax withholding obligations through a “sell to cover” transaction and does not represent a discretionary trade by the reporting person.